Intellia Therapeutics (NTLA) EBITDA: 2015-2025
Historic EBITDA for Intellia Therapeutics (NTLA) over the last 11 years, with Sep 2025 value amounting to -$101.0 million.
- Intellia Therapeutics' EBITDA rose 23.06% to -$101.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$448.1 million, marking a year-over-year increase of 13.42%. This contributed to the annual value of -$518.3 million for FY2024, which is 8.89% down from last year.
- According to the latest figures from Q3 2025, Intellia Therapeutics' EBITDA is -$101.0 million, which was up 0.66% from -$101.7 million recorded in Q2 2025.
- In the past 5 years, Intellia Therapeutics' EBITDA registered a high of -$46.2 million during Q1 2021, and its lowest value of -$152.3 million during Q1 2022.
- Over the past 3 years, Intellia Therapeutics' median EBITDA value was -$121.9 million (recorded in 2023), while the average stood at -$119.2 million.
- In the last 5 years, Intellia Therapeutics' EBITDA plummeted by 229.53% in 2022 and then surged by 35.43% in 2023.
- Quarterly analysis of 5 years shows Intellia Therapeutics' EBITDA stood at -$83.7 million in 2021, then tumbled by 33.22% to -$111.5 million in 2022, then dropped by 17.35% to -$130.8 million in 2023, then decreased by 0.57% to -$131.6 million in 2024, then rose by 23.06% to -$101.0 million in 2025.
- Its EBITDA was -$101.0 million in Q3 2025, compared to -$101.7 million in Q2 2025 and -$113.9 million in Q1 2025.